Pharmaceutical US drug major Bristol-Myers Squibb (NYSE: BMY), which is awaiting a decision from the Food and Drug Administration on March 26 (delayed from last December) regarding approval of its melanoma drug candidate ipilimumab, revealed that, in a clinical trial known as study 024, this investigational compound met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma, a fatal form of skin cancer. 23 March 2011